Cytomedix Company Profile (OTCMKTS:CMXI)

About Cytomedix

Cytomedix logoNuo Therapeutics, Inc., formerly Cytomedix, Inc., is a regenerative therapies company developing and marketing products within the United States and internationally through its strategic partners. The Company commercializes cell-based technologies that harness the regenerative capacity of the human body to trigger natural healing. The Company's commercial offerings are centered on its point of care platform technologies for the separation of blood and bone marrow to produce platelet based therapies or cell concentrates. It is promoting two distinct platelet rich plasma (PRP) technologies: the Aurix System for wound care, and the Angel concentrated Platelet Rich Plasma (cPRP) System for orthopedics and cardiovascular markets. The Company is focused on developing product candidates utilizing the Bright Cell technology platform, owned by its subsidiary, Aldagen, Inc.

Industry, Sector and Symbol:
  • Sector: N/A
  • Industry: N/A
  • Sub-Industry: N/A
  • Exchange: OTCMKTS
  • Symbol: CMXI
  • CUSIP:
Key Metrics:
  • Previous Close: $0.00
  • 50 Day Moving Average: $0.00
  • 200 Day Moving Average: $0.00
  • Trailing P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $N/A
Additional Links:

Analyst Ratings

Consensus Ratings for Cytomedix (OTCMKTS:CMXI) (?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for Cytomedix (OTCMKTS:CMXI)
Show:
No equities research coverage for this company has been tracked by MarketBeat.com

Earnings

Earnings History for Cytomedix (OTCMKTS:CMXI)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/22/2014($0.04)($0.05)ViewN/AView Earnings Details
4/2/2014($0.04)($0.05)ViewN/AView Earnings Details
11/12/2013Q3($0.04)($0.05)ViewListenView Earnings Details
3/18/20134Q12($0.04)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Cytomedix (OTCMKTS:CMXI)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Cytomedix (OTCMKTS:CMXI)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Cytomedix (OTCMKTS:CMXI)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/6/2014Dean TozerInsiderBuy33,300$0.36$11,988.00View SEC Filing  
9/12/2014Dean TozerInsiderBuy40,000$0.45$18,000.00View SEC Filing  
8/29/2014Dean TozerInsiderBuy40,000$0.35$14,000.00View SEC Filing  
8/26/2014Steven A ShallcrossCFOBuy27,500$0.38$10,450.00View SEC Filing  
8/22/2014Dean TozerInsiderBuy38,700$0.38$14,706.00View SEC Filing  
8/20/2014Dean TozerInsiderBuy48,000$0.39$18,720.00View SEC Filing  
8/20/2014Martin P RosendaleCEOBuy25,000$0.40$10,000.00View SEC Filing  
8/20/2014Steven A ShallcrossCFOBuy52,000$0.39$20,280.00View SEC Filing  
5/21/2013David Emerson JordenDirectorBuy80,000$0.50$40,000.00View SEC Filing  
4/19/2013David Emerson JordenDirectorBuy50,000$0.51$25,500.00View SEC Filing  
4/9/2013David Emerson JordenDirectorBuy75,000$0.51$38,250.00View SEC Filing  
4/4/2013Martin P RosendaleCEOBuy17,231$0.52$8,960.12View SEC Filing  
2/27/2013David Emerson JordenDirectorBuy25,000$0.52$13,000.00View SEC Filing  
2/22/2013Aldagen Holdings, LlcInsiderBuy281,819$0.55$155,000.45View SEC Filing  
2/22/2013David Emerson JordenDirectorBuy50,000$0.53$26,500.00View SEC Filing  
2/22/2013Martin P RosendaleCEOBuy20,000$0.53$10,600.00View SEC Filing  
2/19/2013Guercio Joseph DelDirectorBuy509,091$0.55$280,000.05View SEC Filing  
9/14/2012David Emerson JordenDirectorBuy25,000$0.89$22,250.00View SEC Filing  
9/11/2012David Emerson JordenDirectorBuy8,333$0.95$7,916.35View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headlines for Cytomedix (OTCMKTS:CMXI)
No headlines for this company have been tracked by MarketBeat.com

Social

Cytomedix (OTCMKTS:CMXI) Chart for Tuesday, September, 27, 2016


Last Updated on 9/27/2016 by MarketBeat.com Staff